ZIOPHARM Shares Up 3% Premarket Ahead Of Q3 Earnings Report Aftermarket Monday; Earlier Announced Will Present 4 Abstracts At SNO, Including Update To Survival Data From Phase 1 Trial Of Ad-RTS-hIL-12 For Treatment Of GBM